An Oncolytic Vaccinia Virus Expressing Anti-CD47 Nanobody Exerts Enhanced Antitumor Activity by Mediating Innate and Adaptive Immune Cell Infiltration and Activation in the Lymphoma Tumor Microenvironment

Arming oncolytic vaccine virus with a CD47-blocking nanobody and IgG1 Fc created a dual-functional therapeutic platform, offering a paradigm-shifting strategy for lymphoma immunotherapy through coordinated innate and adaptive immune activation.